Radioactive injection targets Tough-to-Treat cancers in new trial
NCT ID NCT07229768
First seen Nov 17, 2025 · Last updated Apr 19, 2026 · Updated 23 times
Summary
This early-stage study is testing a new radioactive drug injection called 177Lu-CTR-FAPI in patients with advanced, metastatic cancers like pancreatic cancer. The main goals are to see if the treatment is safe, to measure how much radiation reaches the tumors, and to check if it helps shrink them. It is for people whose cancer has continued to grow despite standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai General Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.